BioSpace News Archive

Early Studies Show TNX-3500 Significantly Inhibits SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir

BioSpace, Inc. announced today it has acquired MedReps, the leading career platform for medical sales positions. The acquisition strengthens the Company’s position as the leader in online recruitment for the life sciences industry.

Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of April 19, 2021, based on voting indications, Proposal 1 is expected to be approved at the Special Meeting completing the transaction.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors, effective April 15, 2021.

Windtree Therapeutics, Inc. today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT).

CRH Medical Corp.'s securityholders approved the acquisition of CRH by a subsidiary of WELL Health at the special meeting of CRH securityholders on Friday April 16, 2021 . The transaction is expected to be completed on or about April 22, 2021 and represents WELL’s largest acquisition to date with a total transaction value of approximately US$369.2 million .

GATC Health , an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that it has granted an exclusive license for its diabetes platform to GATC DB Care Corp. GATC DB Care was formed specifically to continue development and productization of the GATC Health diabetes platform

Two-Year Results Demonstrating Long-Term Effectiveness of Aerin Medical’s VivAer ® Treatment of Nasal Obstruction Published in International Forum of Allergy &Rhinology Data shows in-office treatment of nasal valve collapse resulted in lasting improvement in symptoms and quality of life SUNNYVALE, Calif.--( BUSINESS WIRE )-- Aerin Medical today announced the publication of two-year results from a multi-center, prospective study that demonstra

CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb ® blood purification technology is intended to treat deadly conditions in critically-ill and cardiac surgery patients, announces that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its investigational device exemption application

Otonomy, Inc. announced the closing of its previously announced underwritten public offering of 8,298,890 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and pre-funded warrants to purchase up to 7,111,110 shares of its common stock for total gross proceeds of approximately $34.7 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Otonomy.